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Antibiotic  overconsumption  and  subsequent  bacterial  multidrug  resistance  are  associated  with  increased
mortality,  length  of hospitalisation  and  healthcare  costs.  Discontinuation  of antibiotic  treatment  in  severe
infections,  such  as bloodstream  infections  (BSIs),  is a  demanding  clinical  decision.  In this  review, we
aim  to  investigate  the  usefulness  of  procalcitonin  (PCT)  monitoring  in  guiding  appropriate  treatment
duration  in BSIs  and  its  impact  on  clinical  outcomes.  Data  from  clinical  studies  conducted  after  2005  that
included  patients  with  BSIs  indicate  that change  of  PCT  is  an  early  indicator  for prognosis  in  terms  of
survival  and,  overall,  support  the  usefulness  of a PCT-guided  clinical  algorithm  in reducing  the  duration
of  antibiotic  treatment  without  compromising  survival.  Furthermore,  the  presented  data  indicate  that
PCT assessment  is helpful  in  the  diagnosis  of  infective  endocarditis.  In conclusion,  monitoring  of PCT
together  with  evaluation  of  the clinical  situation  is a valuable  tool in  reducing  the length  of  antimicrobial
treatment  in BSIs.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Emerging bacterial resistance to multiple antimicrobial agents
rges the need for more efﬁcient strategies to reduce the use
f antimicrobial agents in self-limited and non-bacterial diseases
nd to shorten the duration of antibiotic treatment in bacterial
nfections. Moreover, antibiotic consumption and acquired antimi-
robial resistance have been shown to be associated with increased
ength of hospitalisation and increased healthcare costs [1].
Bloodstream infections (BSIs) are a signiﬁcant cause of mortal-
ty. The rate of misuse of antimicrobials for treatment of BSIs has
een reported to be 41–85% [2]. This results mainly from the ini-
ial 48–72-h period of empirical treatment before the antibiogram
ecomes available. It is evident that we are in need of techniques
hat provide a rapid indication for de-escalation or stopping of
ntimicrobial therapy. The most promising biomarker in guiding
hese therapeutic decisions is procalcitonin (PCT) [3].
Plasma PCT rises within 3–6 h from initial clinical manifestation
f sepsis and falls when severe infection is controlled [4]. High PCT
oncentrations are typically found in bacterial infections, whereas
ower levels predominate in viral infections, and levels <0.1 ng/mL
∗ Corresponding author at: 4th Department of Internal Medicine, ATTIKON Uni-
ersity Hospital, 1 Rimini Street, 12462 Athens, Greece. Tel.: +30 210 58 31 985;
ax:  +30 210 53 26 446.
E-mail address: I.Pantelidou@med.uoa.gr (I.-M. Pantelidou).
ttp://dx.doi.org/10.1016/j.ijantimicag.2015.10.005
924-8579/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
in patients without infection [5]. BSIs are a potent stimulus for PCT
production [6].
In this review, we present the results of clinical studies that
aimed to decipher the role of serial PCT measurements as a tool
to shorten antibiotic treatment duration.
2. Current problems in guiding antimicrobial treatment
It is well established that delay in initiation of effective antimi-
crobial therapy is associated with poor sepsis outcome. Kumar et al.
postulated that initiation of effective antimicrobial therapy within
the ﬁrst hour following onset of septic shock-related hypotension
was associated with 79.9% survival to hospital discharge [7]. Every
additional hour delay until start of effective antimicrobial initiation
was associated with a signiﬁcant decrease in the chance of survival
of 7.6%. However, the study also demonstrated the existence of sub-
stantial delay until start of effective antimicrobials in septic shock.
More precisely, among patients who  were not already receiving
effective therapy, the median time to start of effective antimicrobial
therapy following onset of hypotension was 6 h [7].
Most laboratories report the results of blood cultures after
24–48 h. Even in that case, microbiology diagnosis fails in >50%
of patients with severe infections. Bouza et al. found that the
delay until the ﬁnal microbiological report becomes available is
an independent risk factor for infection-related mortality [8];
the risk of death increases 1.2-fold for each day until deﬁnitive
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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icrobiological information is available. Furthermore, ineffective
mpirical therapy had a dramatic impact on the presence of
lostridium difﬁcile-associated diarrhoea and prolonged the length
f hospital stay.
In light of the failure of pathogen detection and the increase in
isk of death with the time delay of delivery of a proper micro-
iology report, prognosis becomes an everyday calamity with the
mergence of multidrug-resistant pathogens; this leads to inap-
ropriate empirical treatment with unpredictable outcome. In a
ecent study among patients with BSIs from 46 Greek hospitals
onducted by Koupetori et al., the most frequent isolates for infec-
ions admitted in the emergency department were Escherichia coli
nd Klebsiella pneumoniae [9]. Production of extended-spectrum -
actamases (ESBLs) during the period 2010–2013 reached 27.1% in
omparison with 16.4% the previous years (2006–2009) (P = 0.016),
nd production of KPC carbapenemases increased from 7.5% to
4.8% respectively (P = 0.031). Reported resistance rates were far
reater for patients with infections acquired after admission to the
ntensive care unit (ICU), reaching 75% for carbapenems.
To achieve prompt initiation of appropriate antibiotic treatment
f severe infections and to eliminate needless prolonged antibiotic
dministration, clinical algorithms that co-evaluate PCT kinetics
ave been developed and shown to provide useful information.
. The role of procalcitonin
.1. Change of procalcitonin to inform about prognosis
Several prospective studies have tried to explore whether early
hange of serum PCT can advise on ﬁnal outcome. This could be
xtrapolated as information for the appropriateness of adminis-
ered antimicrobial therapy in case microbiology is not available.
 prospective multicentre study by Georgopoulou et al. conducted
n 15 Greek hospital departments enrolled 289 septic patients in
he general ward or the ICU; 33.4% had BSIs [10]. The study showed
hat a decrease of serum PCT by at least 30% or its persistence at
evels <0.25 ng/mL within the ﬁrst 48 h since the onset of empiri-
al antimicrobial treatment was an indicator of favourable survival
utcome [odds ratio (OR) for death = 0.328, 95% conﬁdence inter-
als (CI) 0.173–0.621; P = 0.001]. In contrast, increased or stable PCT
alues indicated inappropriateness of the administered antimicro-
ials (OR = 2.519, 95% CI 1.495–4.245; P = 0.003).
The importance of change of PCT as an early indicator for prog-
osis was conﬁrmed by retrospective analysis of data from two
ndependent US critical care settings by Schuetz et al. [11]. PCT
inetics within the ﬁrst 72 h was found to be an accurate mor-
ality predictor, independently of initial severity assessment. In
articular, a 72-h PCT decrease >80% from baseline had a 90% neg-
tive predictive value to predict death, whereas no decrease or an
ncrease in PCT over 72 h had a positive predictive value of 50%.
.2. Procalcitonin can advise stopping of treatment
The efﬁcacy of a PCT-based algorithm in comparison with
tandard guidelines on antibiotic use was tested in a multicen-
re randomised trial in emergency departments of six tertiary care
ospitals in Switzerland [12]; 1359 patients with lower respi-
atory tract infection were enrolled. Among 925 patients with
ommunity-acquired pneumonia, 72 (7.8%) had positive blood cul-
ures. The study endpoint was the validity of the tested algorithm
o reduce antibiotic exposure without increasing the risk of adverse
utcomes. PCT was measured on admission, on Days 3, 5 and 7, and
t discharge. According to the PCT algorithm, initiation or continu-
tion of antibiotics was strongly discouraged if PCT was <0.1 g/L
nd was discouraged if levels were ≤0.25 g/L; initiation orl Journal of Antimicrobial Agents 46 (2015) S10–S12 S11
continuation of antibiotics was strongly encouraged if PCT was
>0.5 g/L and was  encouraged if levels were >0.25 g/L. The PCT
algorithm was effective in reducing antibiotic exposure: the mean
duration of intravenous antibiotic therapy was reduced by 17.1%
(P < 0.001) and that of oral antibiotic therapy was reduced by 48.5%
(P < 0.001).
In a prospective randomised study by Schroeder et al., the clini-
cal usefulness of PCT in reducing the length of antibiotic treatment
was investigated in surgical intensive care patients [13]: 27 patients
with severe sepsis following abdominal surgery and simultaneous
start of antibiotics were randomly assigned either to a PCT-guided
treatment group (n = 13) or to a control group (n = 14). PCT was mea-
sured daily. Antimicrobials were discontinued if PCT dropped to
1 ng/mL or at least 25% of the initial value for 3 consecutive days.
The duration of antibiotic treatment was 6.6 ± 1.1 days in the PCT-
guided group and 8.3 ± 0.7 days in the control group (P < 0.001). No
negative effects on outcome were observed, whereas the cost of
antibiotic treatment was  reduced by 17.8% (P < 0.01).
A second study regarding surgical patients with severe sep-
sis or septic shock in the ICU retrospectively analysed the effect
of the implementation of a PCT-guided algorithm in antibiotic
consumption, using the same PCT cut-off values [14]. Length of
antibiotic therapy was reduced by an average of 1 day per year, from
14.3 ± 1.2 days in 2005 to 9.0 ± 1.7 days in 2009 (P = 0.02), without
compromising clinical outcomes. Furthermore, this reduction was
associated with a signiﬁcant reduction in re-infection rate (35.1%;
P = 0.014), length of stay in the ICU (2.7 days per year; P < 0.001) and
ventilation hours (42 h per year; P = 0.008).
In contrast to the previous studies, Jensen et al. tested an esca-
lation strategy based on daily PCT measurements in a randomised
controlled open-label trial in critically ill patients in the ICU [15]:
PCT levels >1 ng/mL that were not decreasing more than 10% from
the previous day alerted clinicians to intensify antibiotic treatment.
This algorithm led to a prolonged length of stay in the ICU and sub-
stantially higher use of broad-spectrum antimicrobials. However,
these results could be due to the low microbial resistance rates
of Denmark, where the study was  conducted. Besides, in the sub-
group of patients with veriﬁed BSIs, a shorter time to administration
of appropriate antimicrobials was  observed for the PCT group (0.1
days vs. 0.8 days; P = 0.02).
3.3. Procalcitonin in the diagnosis of infective endocarditis (IE)
PCT appears to be useful in distinguishing patients with IE, thus
guiding appropriate antimicrobial treatment duration. The most
recent prospective study by Knudsen et al. enrolled 759 consecutive
patients with clinical suspicion of IE assessed by transoesophageal
echocardiography [16]; 263 had positive blood cultures. PCT con-
centrations were found to be signiﬁcantly higher in patients with IE
(P < 0.0005), as opposed to C-reactive protein and erythrocyte sed-
imentation rate. Bacteraemia with endocarditis-typical organisms,
speciﬁcally Staphylococcus aureus,  was the strongest independent
determinant of high PCT (P < 0.001). Nevertheless, it was not pos-
sible to identify a clinically useful PCT threshold for diagnosing or
excluding IE.
A previous prospective study by Mueller et al. in 67 consecutive
patients admitted to the hospital with suspicion of IE demonstrated
that PCT levels were signiﬁcantly higher in patients with conﬁrmed
IE compared with those with rejected IE (P < 0.001) [17]. Using a cut-
off value of 2.3 ng/mL, PCT had an 81% sensitivity and 85% speciﬁcity
in predicting IE. The authors recommended the routine use of PCT
in the evaluation of patients with suspected IE in addition to the
established diagnostic criteria.
Jereb et al. evaluated PCT as a diagnostic laboratory parame-
ter in predicting IE among patients with severe infections [18]:
23 patients with IE, 30 patients with sepsis and 30 with viral
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ncephalitis were enrolled in a prospective study. The median
erum PCT level in patients with IE was higher in comparison
ith those with viral encephalitis (P < 0.001); however, distinc-
ion between patients with sepsis and those with IE solely on the
asis of PCT concentration was not possible. The highest PCT levels
ere found in the group of patients with S. aureus endocardi-
is (P = 0.009). Interestingly, median PCT levels were signiﬁcantly
igher among patients with native valve endocarditis than among
atients with prosthetic valve endocarditis (P = 0.002).
The speciﬁcity of PCT in relation to the causative pathogen of
E has also been conﬁrmed in a prospective analysis by Cuculi
t al., who enrolled 77 patients with suspected IE [19]. PCT was
igniﬁcantly elevated among patients with S. aureus endocarditis
ompared with IE due to other pathogens (P = 0.029), concluding
hat PCT has the potential to be used in the early diagnosis of S.
ureus endocarditis.
. Conclusion
Monitoring of PCT is a valuable tool for guiding therapeutic deci-
ions regarding the length of antimicrobial treatment. This strategy
ontributes to less extensive antibiotic treatment with positive
ffects on the development of microbial drug resistance as well
s on health economics. However, adequate interpretation of PCT
oncentrations always requires the evaluation of the clinical pre-
entation.
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